China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

The Chinese government listed Illumina, whose global headquarters is in California, as an “unreliable entity” shortly after ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Illumina (ILMN-5.47%) is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment.